5 Best Pharma Stocks To Buy Now

4. AbbVie Inc. (NYSE:ABBV)

Number of Hedge Fund Holders: 74

AbbVie Inc. (NYSE:ABBV) operates as a specialized biopharmaceutical company committed to the discovery, development, manufacturing, and distribution of medications tailored to address chronic and complex illnesses. The company gained renown for its flagship drug, Humira, a vital treatment for conditions such as moderate-to-severe rheumatoid arthritis and Crohn’s disease.

With a remarkable record of 50 years of continuous dividend growth, the American pharmaceutical giant currently offers a dividend yield of 4.08% as of October 24.

At the conclusion of the second quarter in 2023, data from Insider Monkey’s database, tracking 74 hedge funds, indicated holdings in AbbVie Inc. (NYSE:ABBV), reflecting a slight decrease from the 75 hedge funds in the previous quarter. The combined value of these holdings exceeds $2.37 billion.

Follow Abbvie Inc. (NYSE:ABBV)